Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRP700 single-dose crossover study for cough in idiopathic pulmonary fibrosis
2012-005794-31Phase 2Unknown
- Sponsor
- Verona Pharma
- Start
- Feb 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carcainium chloride in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Verona Pharma. Primary endpoints: 24-hour cough frequency, Cough severity and 1 more. Status: unknown.
02
Drugs
carcainium chloride
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2012-005794-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005794-31.